The Actavis Group is one of the world’s leading players in the development, manufacture and sale of high-quality generic pharmaceuticals.
Actavis’ recent acquisitions have positioned the Group among the world’s largest companies in the industry. Founded in 1956, the Group has more than 11,000 employees operating in about 40 countries around the globe. Its headquarters are in Iceland.
The Company has modern development and manufacturing facilities in Europe, the US and Asia. The plants produce a variety of medicines in different formulations including tablets, capsules, injectables, suppositories, sprays, steriles, powders, oral liquids and semi-solids.
Product portfolio
Actavis offers one of the broadest product portfolios and strongest pipelines in the generics industry:
- Around 650 products on the market
- Over 400 products under development and pending registration
- Products registered in more than 60 countries
- Over 500 product and market launches in Group markets in 2007
- 46-48 ANDAs expected to be filed in the US market in 2008
Future opportunities
An extensive network of sales and marketing offices enables effective market penetration, positioning the Group strongly in the world’s largest markets for generic pharmaceuticals. Strategic acquisitions, the opening of new sales offices and intensive investment in the development of generic pharmaceuticals are fuelling the growth of Actavis and have positioned the Group to take advantage of future opportunities.
The Group remains committed to leading the consolidation of a still fragmented industry through strategic acquisitions and to driving further organic growth through innovative product launches, penetration of new markets and regulatory approvals of new generic pharmaceuticals.
Actavis continues to invest heavily in research and development, pursuing a determined first-to-market strategy and positioning itself to take full advantage of future opportunities.
Click here to view our Corporate Presentation & Fact Sheet.pdf (305.04KB)